Consistent with this, we previously determined that mTOR pathway activity is elevated in metastatic tumors compared to primary tumors and that significant increases in mTOR activity were associated with two or more mutations in the mTOR signaling pathway, which was frequently seen in metastases but not primary tumors [7]. The gene discussed is MTOR; the disease is metastatic neoplasm.